Wednesday, January 25, 2017

BRIEF-Positive topline results show Eisai's Lenvatinib meets primary endpoint

* Positive topline results of large phase 3 trial show

Eisai's lenvatinib meets primary endpoint in unresectable

hepatocellular carcinoma

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)